The money earned by luck and saved by ability is probably the common choice of new crown testing companies that have made a lot of money during the epidemic.
It's not that I'm reluctant to spend it, but there is really too much money, I can't spend it at all, and I have nowhere to spend it, so I can only deposit it in the bank and lie down and eat interest with the most relaxed mentality.
Recently, the listed company Mingde Biotechnology issued an announcement that it plans to take out 4 billion idle funds for entrusted financial management.
At first glance, 4 billion doesn't seem to be too much, but more and less are relative, 4 billion is like a monthly salary of 30 million for Mingde Biotech, and suddenly 5 million is quite a lot.
Of course, the money of Mingde Biotech is not from buying lottery tickets, but from selling new crown detection reagents during the three-year epidemic, which is a powerful ingredient, but it mainly depends on luck, after all, in those three years, as long as you can produce it, you can basically make money.
Mingde Biotech was listed in 2018, and its main business is "POCT" (Point of Care Testing), which is called "point-of-care testing" in Chinese, which is simply point-of-care testing, testing at that time, and results at that time.
The concept of POCT may be difficult for everyone to understand before the new crown, but after experiencing the new crown, you will understand that it takes two days to know the result of a nucleic acid test in the early stage of the new crown, and then the waiting time is getting shorter and shorter.
It is by virtue of its first-mover advantage in "POCT" that Mingde Biotech has grabbed the biggest cake of new crown point-of-care testing in the post-epidemic era in 2022 and has become a big winner.
Querying historical data, Mingde Biotech's revenue in 2018 and 2019 was 176 million and 181 million respectively, and the profits were 61 million and 41 million respectively.
But to be honest, if you want to save 4 billion idle funds with such data, I'm afraid a century is not enough, and as soon as the new crown epidemic came, Mingde Biotech earned 6 billion in 3 years.
The above figure is the total revenue, new crown testing revenue, and total profit data of Mingde Biotech from 2019 to 2023, as mentioned earlier, the most important harvest year of Mingde Biotech is 2022.
According to the 2022 annual report, Mingde Biotech sold a total of about 3.62 billion diagnostic reagents that year, which can be covered twice based on the national population, directly earning 10.5 billion in revenue and making a net profit of 4.2 billion
Mingde Biotech originally only had a scale of one or two hundred million yuan per year, and the sudden extra money really couldn't find a place to go, so like other listed companies that couldn't spend enough money, they chose the most stable bank financial management.
In fact, the announcement of the 4 billion wealth management product purchase plan of Mingde Biotech is just a routine disclosure procedure for listed companies, and all the money that cannot be spent has been deposited in the bank last year.
According to the 2023 annual report, Mingde Biotech has 3.6 billion large certificates of deposit in its non-current assets, contributing 120 million yuan of interest income, and it is this interest that keeps Mingde Biotech from losing money in 2023.
Of course, the deduction of non-losses in 2023 is due to the provision of bad debts left during the epidemic, but it is undeniable that with the departure of the new crown, Mingde Biotech is changing back to its original shape, and will it really rely on the interest relief of financial management in the future?
In fact, the 4 billion wealth management of Mingde Biotech is considered to be less, and Jiu'an Medical, which made a huge fortune during the new crown epidemic, is the leader in buying bank wealth management for listed companies.
In February 2023, Jiu'an Medical issued an announcement that it planned to use 20 billion idle funds for financial investment, of which 17 billion was entrusted to bank wealth management and 3 billion was used to buy stocks, and two months later, it was announced that it would add another 2.8 billion entrusted financial management.
Take 21.8 billion wealth management at a time, which can be regarded as a ceiling for financial management of listed companies.
In fact, it is not only listed companies that have made money from the new crown epidemic to buy wealth management, but also A-shares, and listed companies are becoming more and more popular to buy wealth management products, especially those who use over-raised funds and temporarily idle funds after raising funds for financial management.
Of course, the money is earned by the people themselves, whether it is by luck or strength, it is all legally obtained, and they can do whatever they want, but the gray pigeon also has a doubt: shareholders take out the money from the bank and put it in the stock market, and the listed company deposits the financing money in the bank.
The original intention of the stock market is to serve the real economy, and the money invested by 200 million shareholders and hundreds of millions of people in the stock market is also to support listed companies to engage in production and economy, and then get a little dividend return by the way.
And now listed companies are not good at seeking development, and they buy bank wealth management at every turn, to a certain extent, this is not the "internal circulation" that the state wants to crack down.
Back to Mingde Biology, the money is not spent for a while, 4 billion entrusted financial management, more than 1,000 people, just rely on the interest of more than 100 million a year is not enough to survive, and its own hematopoietic ability is the key.
In 2012, it was the two of them who joined forces to launch a high-throughput intelligent POCT immunoassay platform in China, opening up the market with the advantage of leading technology.
After experiencing this epidemic, the dividends in three years were nearly 1.3 billion, and the two of them fell into more than 500 million, and their pockets were not the same as in the past.
I remember that when the performance of Mingde Biotech was singing in 2022, some investors asked questions on the platform, asking how the name "Mingde Bio" came from?
The secretary of the board of directors of Mingde Biotech replied:
"The way of the university, in Mingmingde, the purpose of the university is to promote the moral character of uprightness, in the same way, the health cause, in Mingmingde, for individuals, the way of a gentleman, in Mingmingde. The name of the company reflects the original intention of the two founders and the personal supreme requirements and hopes for the industry they are engaged in and the company in this format. ”
In fact, in the stock market, you don't need to have such high requirements, just don't let down the stockholders.